Deuterium-enriched SDX-101

Details Deuterium-enriched SDX-101 Deuterium-enriched SDX-101

2011-06-07

2011-06-07

Saeed, Kamal A (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S430000, C548S432000

Reexamination Certificate

active

07956080

ABSTRACT:
The present application describes deuterium-enriched SDX-101, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.

REFERENCES:
patent: 3823681 (1974-07-01), Cushing et al.
patent: 9526325 (1995-10-01), None
Demerson et al., Resolution of Etodolac and Antiinflammatory and Prostaglandin Synthetase Inhibiting Properties of the Enantiomers, 1983, J. Med. Chem., 26, 1778-1780.
Kushner, D.J.; Pharmacological Uses and Perspectives of Heavy Water and Deuterated Compounds; Canadian Journal of Physiology and Pharmacology 1999, 77(2), 79-88.
Jerry March, Advance Organic Chemistry, Fourth Edition, published 1992, pp. 226-230.
Ferdinandi E.S. et al., Disposition and Biotransformation of 14C-Etodolac in Man, Xenobiotica 1986, 16(2), 153-66. Abstract Only.
Tougou K. et al. Stereoselective glucuronidation and hydroxylation of etodolac by UGT1A9 and CYP2C9 in man, Xenobiotica 2004, 34(5), 449-61.

Affiliated with

Also associated with

Rating

Deuterium-enriched SDX-101 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Deuterium-enriched SDX-101, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Deuterium-enriched SDX-101 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2716807